nodes	percent_of_prediction	percent_of_DWPC	metapath
Tranexamic Acid—PLG—prostate gland—urinary bladder cancer	0.0366	0.195	CbGeAlD
Tranexamic Acid—PLG—epithelium—urinary bladder cancer	0.0269	0.143	CbGeAlD
Tranexamic Acid—PLG—smooth muscle tissue—urinary bladder cancer	0.0259	0.138	CbGeAlD
Tranexamic Acid—PLG—renal system—urinary bladder cancer	0.025	0.133	CbGeAlD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—IGFBP3—urinary bladder cancer	0.0202	0.0687	CbGpPWpGaD
Tranexamic Acid—PLG—female reproductive system—urinary bladder cancer	0.02	0.106	CbGeAlD
Tranexamic Acid—PLG—Dissolution of Fibrin Clot—PLAU—urinary bladder cancer	0.0153	0.0523	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—SLC19A1—urinary bladder cancer	0.0144	0.0491	CbGpPWpGaD
Tranexamic Acid—SLC15A2—prostate gland—urinary bladder cancer	0.0117	0.0624	CbGeAlD
Tranexamic Acid—PLG—Blood Clotting Cascade—PLAU—urinary bladder cancer	0.0101	0.0343	CbGpPWpGaD
Tranexamic Acid—SLC15A2—seminal vesicle—urinary bladder cancer	0.00991	0.0528	CbGeAlD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—MPO—urinary bladder cancer	0.00985	0.0336	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—BIRC3—urinary bladder cancer	0.00904	0.0308	CbGpPWpGaD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—IGF1—urinary bladder cancer	0.00852	0.029	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—MPO—urinary bladder cancer	0.00801	0.0273	CbGpPWpGaD
Tranexamic Acid—SLC15A2—renal system—urinary bladder cancer	0.00798	0.0425	CbGeAlD
Tranexamic Acid—SLC15A2—urethra—urinary bladder cancer	0.00784	0.0418	CbGeAlD
Tranexamic Acid—PLG—amb2 Integrin signaling—PLAU—urinary bladder cancer	0.00747	0.0254	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—LOXL4—urinary bladder cancer	0.00737	0.0251	CbGpPWpGaD
Tranexamic Acid—SLC15A2—female reproductive system—urinary bladder cancer	0.00639	0.034	CbGeAlD
Tranexamic Acid—PLG—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.00637	0.0217	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.00618	0.0211	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—PLAU—urinary bladder cancer	0.00601	0.0205	CbGpPWpGaD
Tranexamic Acid—SLC15A2—vagina—urinary bladder cancer	0.00578	0.0308	CbGeAlD
Tranexamic Acid—PLG—Extracellular matrix organization—LOXL1—urinary bladder cancer	0.00559	0.019	CbGpPWpGaD
Tranexamic Acid—PLG—Syndecan-4-mediated signaling events—RHOA—urinary bladder cancer	0.00557	0.019	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—RHOA—urinary bladder cancer	0.00557	0.019	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.00544	0.0186	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—SOD2—urinary bladder cancer	0.00503	0.0171	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—GPX1—urinary bladder cancer	0.0048	0.0164	CbGpPWpGaD
Tranexamic Acid—PLG—Complement and Coagulation Cascades—PLAU—urinary bladder cancer	0.00458	0.0156	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—MTHFR—urinary bladder cancer	0.00443	0.0151	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—MMP9—urinary bladder cancer	0.00442	0.0151	CbGpPWpGaD
Tranexamic Acid—PLG—Syndecan-4-mediated signaling events—MMP9—urinary bladder cancer	0.00442	0.0151	CbGpPWpGaD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP9—urinary bladder cancer	0.00442	0.0151	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.004	0.0136	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.00381	0.013	CbGpPWpGaD
Tranexamic Acid—SLC15A2—lymph node—urinary bladder cancer	0.00374	0.0199	CbGeAlD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—urinary bladder cancer	0.00356	0.0121	CbGpPWpGaD
Tranexamic Acid—SLC15A2—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00353	0.012	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.00352	0.012	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—TNF—urinary bladder cancer	0.0034	0.0116	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—SRC—urinary bladder cancer	0.00328	0.0112	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00314	0.0107	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—urinary bladder cancer	0.00308	0.0105	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—RHOA—urinary bladder cancer	0.00301	0.0103	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—IGF1—urinary bladder cancer	0.00292	0.00995	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—urinary bladder cancer	0.00288	0.0098	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.00278	0.00948	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—CDH1—urinary bladder cancer	0.0027	0.00919	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—IL2—urinary bladder cancer	0.00262	0.00892	CbGpPWpGaD
Tranexamic Acid—PLG—Orphan transporters—CREBBP—urinary bladder cancer	0.0024	0.00817	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—TNF—urinary bladder cancer	0.00238	0.00812	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.00234	0.00799	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.00227	0.00774	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.00224	0.00765	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—CDX2—urinary bladder cancer	0.00198	0.00675	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP9—urinary bladder cancer	0.00195	0.00665	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—TNF—urinary bladder cancer	0.00191	0.0065	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00185	0.00631	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—FGFR3—urinary bladder cancer	0.0018	0.00614	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00179	0.00611	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—TP53—urinary bladder cancer	0.00168	0.00573	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—TP53—urinary bladder cancer	0.00162	0.00553	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.00152	0.00516	CbGpPWpGaD
Tranexamic Acid—Arrhythmia—Gemcitabine—urinary bladder cancer	0.0014	0.00269	CcSEcCtD
Tranexamic Acid—Musculoskeletal pain—Doxorubicin—urinary bladder cancer	0.0014	0.00269	CcSEcCtD
Tranexamic Acid—Pulmonary embolism—Doxorubicin—urinary bladder cancer	0.00138	0.00266	CcSEcCtD
Tranexamic Acid—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.00138	0.00266	CcSEcCtD
Tranexamic Acid—Myalgia—Thiotepa—urinary bladder cancer	0.00138	0.00266	CcSEcCtD
Tranexamic Acid—Arthralgia—Thiotepa—urinary bladder cancer	0.00138	0.00266	CcSEcCtD
Tranexamic Acid—Arrhythmia—Fluorouracil—urinary bladder cancer	0.00137	0.00265	CcSEcCtD
Tranexamic Acid—Eye disorder—Cisplatin—urinary bladder cancer	0.00136	0.00263	CcSEcCtD
Tranexamic Acid—Flushing—Cisplatin—urinary bladder cancer	0.00135	0.00261	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00135	0.00261	CcSEcCtD
Tranexamic Acid—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.00133	0.00256	CcSEcCtD
Tranexamic Acid—Back pain—Gemcitabine—urinary bladder cancer	0.00132	0.00254	CcSEcCtD
Tranexamic Acid—Polyuria—Methotrexate—urinary bladder cancer	0.00132	0.00254	CcSEcCtD
Tranexamic Acid—Immune system disorder—Cisplatin—urinary bladder cancer	0.00132	0.00254	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00131	0.00253	CcSEcCtD
Tranexamic Acid—Arrhythmia—Cisplatin—urinary bladder cancer	0.0013	0.00251	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.0013	0.00442	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.0013	0.00442	CbGpPWpGaD
Tranexamic Acid—Nervous system disorder—Thiotepa—urinary bladder cancer	0.0013	0.0025	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—ERBB2—urinary bladder cancer	0.00128	0.00437	CbGpPWpGaD
Tranexamic Acid—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.00126	0.00244	CcSEcCtD
Tranexamic Acid—Anaemia—Gemcitabine—urinary bladder cancer	0.00126	0.00243	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.00125	0.00426	CbGpPWpGaD
Tranexamic Acid—Eye disorder—Etoposide—urinary bladder cancer	0.00125	0.00241	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.00124	0.00424	CbGpPWpGaD
Tranexamic Acid—Cardiac disorder—Etoposide—urinary bladder cancer	0.00124	0.00239	CcSEcCtD
Tranexamic Acid—Flushing—Etoposide—urinary bladder cancer	0.00124	0.00239	CcSEcCtD
Tranexamic Acid—Anaemia—Fluorouracil—urinary bladder cancer	0.00124	0.00239	CcSEcCtD
Tranexamic Acid—Malaise—Gemcitabine—urinary bladder cancer	0.00123	0.00237	CcSEcCtD
Tranexamic Acid—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.00123	0.00237	CcSEcCtD
Tranexamic Acid—Visual disturbance—Methotrexate—urinary bladder cancer	0.00122	0.00235	CcSEcCtD
Tranexamic Acid—Muscle spasms—Cisplatin—urinary bladder cancer	0.00122	0.00235	CcSEcCtD
Tranexamic Acid—Angiopathy—Etoposide—urinary bladder cancer	0.00121	0.00234	CcSEcCtD
Tranexamic Acid—Immune system disorder—Etoposide—urinary bladder cancer	0.00121	0.00233	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Etoposide—urinary bladder cancer	0.0012	0.00232	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.0012	0.00232	CcSEcCtD
Tranexamic Acid—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00119	0.0023	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.00119	0.00404	CbGpPWpGaD
Tranexamic Acid—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.00118	0.00228	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.00118	0.00227	CcSEcCtD
Tranexamic Acid—Anaemia—Cisplatin—urinary bladder cancer	0.00117	0.00226	CcSEcCtD
Tranexamic Acid—Dyspepsia—Thiotepa—urinary bladder cancer	0.00116	0.00224	CcSEcCtD
Tranexamic Acid—Convulsion—Fluorouracil—urinary bladder cancer	0.00116	0.00224	CcSEcCtD
Tranexamic Acid—Chest pain—Gemcitabine—urinary bladder cancer	0.00116	0.00223	CcSEcCtD
Tranexamic Acid—Myalgia—Gemcitabine—urinary bladder cancer	0.00116	0.00223	CcSEcCtD
Tranexamic Acid—Arthralgia—Gemcitabine—urinary bladder cancer	0.00116	0.00223	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—IFNA2—urinary bladder cancer	0.00116	0.00394	CbGpPWpGaD
Tranexamic Acid—Discomfort—Gemcitabine—urinary bladder cancer	0.00115	0.00221	CcSEcCtD
Tranexamic Acid—Malaise—Cisplatin—urinary bladder cancer	0.00114	0.00221	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00114	0.0022	CcSEcCtD
Tranexamic Acid—Chest pain—Fluorouracil—urinary bladder cancer	0.00114	0.0022	CcSEcCtD
Tranexamic Acid—Myalgia—Fluorouracil—urinary bladder cancer	0.00114	0.0022	CcSEcCtD
Tranexamic Acid—Fatigue—Thiotepa—urinary bladder cancer	0.00114	0.0022	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—CDH1—urinary bladder cancer	0.00113	0.00385	CbGpPWpGaD
Tranexamic Acid—Discomfort—Fluorouracil—urinary bladder cancer	0.00113	0.00217	CcSEcCtD
Tranexamic Acid—Back pain—Etoposide—urinary bladder cancer	0.00112	0.00217	CcSEcCtD
Tranexamic Acid—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00112	0.00216	CcSEcCtD
Tranexamic Acid—Muscle spasms—Etoposide—urinary bladder cancer	0.00112	0.00216	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00111	0.00214	CcSEcCtD
Tranexamic Acid—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.0011	0.00213	CcSEcCtD
Tranexamic Acid—Convulsion—Cisplatin—urinary bladder cancer	0.0011	0.00212	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—CDKN1A—urinary bladder cancer	0.0011	0.00374	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—PTEN—urinary bladder cancer	0.00109	0.00373	CbGpPWpGaD
Tranexamic Acid—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00109	0.00211	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00109	0.0021	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00109	0.0021	CcSEcCtD
Tranexamic Acid—Myalgia—Cisplatin—urinary bladder cancer	0.00108	0.00208	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00108	0.00208	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Etoposide—urinary bladder cancer	0.00108	0.00208	CcSEcCtD
Tranexamic Acid—Anaemia—Etoposide—urinary bladder cancer	0.00107	0.00207	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00107	0.00207	CcSEcCtD
Tranexamic Acid—Discomfort—Cisplatin—urinary bladder cancer	0.00107	0.00206	CcSEcCtD
Tranexamic Acid—Migraine—Epirubicin—urinary bladder cancer	0.00107	0.00205	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00106	0.0036	CbGpPWpGaD
Tranexamic Acid—Malaise—Etoposide—urinary bladder cancer	0.00105	0.00202	CcSEcCtD
Tranexamic Acid—Abdominal pain—Thiotepa—urinary bladder cancer	0.00104	0.00201	CcSEcCtD
Tranexamic Acid—Hypotension—Gemcitabine—urinary bladder cancer	0.00104	0.002	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00104	0.002	CcSEcCtD
Tranexamic Acid—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00103	0.00199	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Etoposide—urinary bladder cancer	0.00102	0.00197	CcSEcCtD
Tranexamic Acid—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00102	0.00197	CcSEcCtD
Tranexamic Acid—Hypotension—Fluorouracil—urinary bladder cancer	0.00102	0.00197	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00102	0.00196	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—SRC—urinary bladder cancer	0.00102	0.00346	CbGpPWpGaD
Tranexamic Acid—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00101	0.00195	CcSEcCtD
Tranexamic Acid—Convulsion—Etoposide—urinary bladder cancer	0.00101	0.00194	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000996	0.00339	CbGpPWpGaD
Tranexamic Acid—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000996	0.00192	CcSEcCtD
Tranexamic Acid—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000991	0.00191	CcSEcCtD
Tranexamic Acid—Chest pain—Etoposide—urinary bladder cancer	0.00099	0.00191	CcSEcCtD
Tranexamic Acid—Migraine—Doxorubicin—urinary bladder cancer	0.000986	0.0019	CcSEcCtD
Tranexamic Acid—Discomfort—Etoposide—urinary bladder cancer	0.000978	0.00189	CcSEcCtD
Tranexamic Acid—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000974	0.00188	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000973	0.00188	CcSEcCtD
Tranexamic Acid—Hypotension—Cisplatin—urinary bladder cancer	0.000968	0.00187	CcSEcCtD
Tranexamic Acid—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000962	0.00185	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000959	0.00185	CcSEcCtD
Tranexamic Acid—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000958	0.00185	CcSEcCtD
Tranexamic Acid—Fatigue—Gemcitabine—urinary bladder cancer	0.000958	0.00185	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000949	0.00183	CcSEcCtD
Tranexamic Acid—Asthenia—Thiotepa—urinary bladder cancer	0.000948	0.00183	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000944	0.00182	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000943	0.00182	CcSEcCtD
Tranexamic Acid—Dyspnoea—Cisplatin—urinary bladder cancer	0.000924	0.00178	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000916	0.00177	CcSEcCtD
Tranexamic Acid—Angina pectoris—Epirubicin—urinary bladder cancer	0.000911	0.00176	CcSEcCtD
Tranexamic Acid—Diarrhoea—Thiotepa—urinary bladder cancer	0.000904	0.00174	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.0009	0.00174	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000894	0.00172	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—HDAC4—urinary bladder cancer	0.00089	0.00303	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—EGFR—urinary bladder cancer	0.00089	0.00303	CbGpPWpGaD
Tranexamic Acid—Hypotension—Etoposide—urinary bladder cancer	0.000887	0.00171	CcSEcCtD
Tranexamic Acid—Renal failure—Methotrexate—urinary bladder cancer	0.000876	0.00169	CcSEcCtD
Tranexamic Acid—Dizziness—Thiotepa—urinary bladder cancer	0.000874	0.00168	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000869	0.00296	CbGpPWpGaD
Tranexamic Acid—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000854	0.00165	CcSEcCtD
Tranexamic Acid—Dyspnoea—Etoposide—urinary bladder cancer	0.000846	0.00163	CcSEcCtD
Tranexamic Acid—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000843	0.00163	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—KRAS—urinary bladder cancer	0.000841	0.00286	CbGpPWpGaD
Tranexamic Acid—Vomiting—Thiotepa—urinary bladder cancer	0.00084	0.00162	CcSEcCtD
Tranexamic Acid—Headache—Thiotepa—urinary bladder cancer	0.000828	0.0016	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—PLAU—urinary bladder cancer	0.00082	0.00279	CbGpPWpGaD
Tranexamic Acid—Renal failure—Epirubicin—urinary bladder cancer	0.00082	0.00158	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000819	0.00158	CcSEcCtD
Tranexamic Acid—Fatigue—Etoposide—urinary bladder cancer	0.000818	0.00158	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP9—urinary bladder cancer	0.000818	0.00279	CbGpPWpGaD
Tranexamic Acid—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000805	0.00155	CcSEcCtD
Tranexamic Acid—Haemoglobin—Methotrexate—urinary bladder cancer	0.000804	0.00155	CcSEcCtD
Tranexamic Acid—Haemorrhage—Methotrexate—urinary bladder cancer	0.0008	0.00154	CcSEcCtD
Tranexamic Acid—Asthenia—Gemcitabine—urinary bladder cancer	0.000797	0.00154	CcSEcCtD
Tranexamic Acid—Nausea—Thiotepa—urinary bladder cancer	0.000785	0.00151	CcSEcCtD
Tranexamic Acid—Sinusitis—Epirubicin—urinary bladder cancer	0.000783	0.00151	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Etoposide—urinary bladder cancer	0.000782	0.00151	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000776	0.0015	CcSEcCtD
Tranexamic Acid—Visual impairment—Methotrexate—urinary bladder cancer	0.000771	0.00149	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000763	0.00147	CcSEcCtD
Tranexamic Acid—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00076	0.00147	CcSEcCtD
Tranexamic Acid—Renal failure—Doxorubicin—urinary bladder cancer	0.000759	0.00146	CcSEcCtD
Tranexamic Acid—Haemoglobin—Epirubicin—urinary bladder cancer	0.000753	0.00145	CcSEcCtD
Tranexamic Acid—Abdominal pain—Etoposide—urinary bladder cancer	0.00075	0.00145	CcSEcCtD
Tranexamic Acid—Haemorrhage—Epirubicin—urinary bladder cancer	0.000749	0.00144	CcSEcCtD
Tranexamic Acid—Eye disorder—Methotrexate—urinary bladder cancer	0.000748	0.00144	CcSEcCtD
Tranexamic Acid—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000748	0.00144	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—GLI1—urinary bladder cancer	0.000746	0.00254	CbGpPWpGaD
Tranexamic Acid—Asthenia—Cisplatin—urinary bladder cancer	0.000743	0.00143	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000743	0.00143	CcSEcCtD
Tranexamic Acid—Angiopathy—Methotrexate—urinary bladder cancer	0.000726	0.0014	CcSEcCtD
Tranexamic Acid—Sinusitis—Doxorubicin—urinary bladder cancer	0.000724	0.0014	CcSEcCtD
Tranexamic Acid—Immune system disorder—Methotrexate—urinary bladder cancer	0.000723	0.00139	CcSEcCtD
Tranexamic Acid—Dizziness—Fluorouracil—urinary bladder cancer	0.000723	0.00139	CcSEcCtD
Tranexamic Acid—Visual impairment—Epirubicin—urinary bladder cancer	0.000722	0.00139	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000721	0.00139	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—HRAS—urinary bladder cancer	0.000714	0.00243	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000714	0.00243	CbGpPWpGaD
Tranexamic Acid—Diarrhoea—Cisplatin—urinary bladder cancer	0.000709	0.00137	CcSEcCtD
Tranexamic Acid—Vomiting—Gemcitabine—urinary bladder cancer	0.000707	0.00136	CcSEcCtD
Tranexamic Acid—Eye disorder—Epirubicin—urinary bladder cancer	0.0007	0.00135	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Etoposide—urinary bladder cancer	0.000699	0.00135	CcSEcCtD
Tranexamic Acid—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000696	0.00134	CcSEcCtD
Tranexamic Acid—Headache—Gemcitabine—urinary bladder cancer	0.000696	0.00134	CcSEcCtD
Tranexamic Acid—Flushing—Epirubicin—urinary bladder cancer	0.000695	0.00134	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000695	0.00134	CcSEcCtD
Tranexamic Acid—Vomiting—Fluorouracil—urinary bladder cancer	0.000695	0.00134	CcSEcCtD
Tranexamic Acid—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000693	0.00134	CcSEcCtD
Tranexamic Acid—Headache—Fluorouracil—urinary bladder cancer	0.000685	0.00132	CcSEcCtD
Tranexamic Acid—Asthenia—Etoposide—urinary bladder cancer	0.000681	0.00131	CcSEcCtD
Tranexamic Acid—Angiopathy—Epirubicin—urinary bladder cancer	0.000679	0.00131	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—CREBBP—urinary bladder cancer	0.000676	0.0023	CbGpPWpGaD
Tranexamic Acid—Immune system disorder—Epirubicin—urinary bladder cancer	0.000676	0.0013	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000675	0.0013	CcSEcCtD
Tranexamic Acid—Back pain—Methotrexate—urinary bladder cancer	0.000674	0.0013	CcSEcCtD
Tranexamic Acid—Arrhythmia—Epirubicin—urinary bladder cancer	0.000669	0.00129	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—IGF1—urinary bladder cancer	0.000668	0.00228	CbGpPWpGaD
Tranexamic Acid—Visual impairment—Doxorubicin—urinary bladder cancer	0.000668	0.00129	CcSEcCtD
Tranexamic Acid—Nausea—Gemcitabine—urinary bladder cancer	0.00066	0.00127	CcSEcCtD
Tranexamic Acid—Vomiting—Cisplatin—urinary bladder cancer	0.000659	0.00127	CcSEcCtD
Tranexamic Acid—Diarrhoea—Etoposide—urinary bladder cancer	0.000649	0.00125	CcSEcCtD
Tranexamic Acid—Nausea—Fluorouracil—urinary bladder cancer	0.000649	0.00125	CcSEcCtD
Tranexamic Acid—Eye disorder—Doxorubicin—urinary bladder cancer	0.000647	0.00125	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000646	0.00125	CcSEcCtD
Tranexamic Acid—Anaemia—Methotrexate—urinary bladder cancer	0.000644	0.00124	CcSEcCtD
Tranexamic Acid—Flushing—Doxorubicin—urinary bladder cancer	0.000643	0.00124	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000643	0.00124	CcSEcCtD
Tranexamic Acid—Back pain—Epirubicin—urinary bladder cancer	0.00063	0.00122	CcSEcCtD
Tranexamic Acid—Angiopathy—Doxorubicin—urinary bladder cancer	0.000629	0.00121	CcSEcCtD
Tranexamic Acid—Malaise—Methotrexate—urinary bladder cancer	0.000628	0.00121	CcSEcCtD
Tranexamic Acid—Dizziness—Etoposide—urinary bladder cancer	0.000628	0.00121	CcSEcCtD
Tranexamic Acid—Muscle spasms—Epirubicin—urinary bladder cancer	0.000627	0.00121	CcSEcCtD
Tranexamic Acid—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000626	0.00121	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000624	0.0012	CcSEcCtD
Tranexamic Acid—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000619	0.00119	CcSEcCtD
Tranexamic Acid—Nausea—Cisplatin—urinary bladder cancer	0.000615	0.00119	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—RHOA—urinary bladder cancer	0.000612	0.00209	CbGpPWpGaD
Tranexamic Acid—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000605	0.00117	CcSEcCtD
Tranexamic Acid—Convulsion—Methotrexate—urinary bladder cancer	0.000603	0.00116	CcSEcCtD
Tranexamic Acid—Vomiting—Etoposide—urinary bladder cancer	0.000603	0.00116	CcSEcCtD
Tranexamic Acid—Anaemia—Epirubicin—urinary bladder cancer	0.000602	0.00116	CcSEcCtD
Tranexamic Acid—Headache—Etoposide—urinary bladder cancer	0.000595	0.00115	CcSEcCtD
Tranexamic Acid—Chest pain—Methotrexate—urinary bladder cancer	0.000593	0.00114	CcSEcCtD
Tranexamic Acid—Myalgia—Methotrexate—urinary bladder cancer	0.000593	0.00114	CcSEcCtD
Tranexamic Acid—Arthralgia—Methotrexate—urinary bladder cancer	0.000593	0.00114	CcSEcCtD
Tranexamic Acid—Malaise—Epirubicin—urinary bladder cancer	0.000588	0.00113	CcSEcCtD
Tranexamic Acid—Discomfort—Methotrexate—urinary bladder cancer	0.000586	0.00113	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000586	0.002	CbGpPWpGaD
Tranexamic Acid—Back pain—Doxorubicin—urinary bladder cancer	0.000583	0.00112	CcSEcCtD
Tranexamic Acid—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00058	0.00112	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000573	0.0011	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000568	0.0011	CcSEcCtD
Tranexamic Acid—Convulsion—Epirubicin—urinary bladder cancer	0.000565	0.00109	CcSEcCtD
Tranexamic Acid—Nausea—Etoposide—urinary bladder cancer	0.000564	0.00109	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00056	0.00108	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000557	0.00107	CcSEcCtD
Tranexamic Acid—Anaemia—Doxorubicin—urinary bladder cancer	0.000557	0.00107	CcSEcCtD
Tranexamic Acid—Chest pain—Epirubicin—urinary bladder cancer	0.000555	0.00107	CcSEcCtD
Tranexamic Acid—Arthralgia—Epirubicin—urinary bladder cancer	0.000555	0.00107	CcSEcCtD
Tranexamic Acid—Myalgia—Epirubicin—urinary bladder cancer	0.000555	0.00107	CcSEcCtD
Tranexamic Acid—Discomfort—Epirubicin—urinary bladder cancer	0.000548	0.00106	CcSEcCtD
Tranexamic Acid—Malaise—Doxorubicin—urinary bladder cancer	0.000544	0.00105	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000532	0.00103	CcSEcCtD
Tranexamic Acid—Hypotension—Methotrexate—urinary bladder cancer	0.000531	0.00102	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00053	0.00102	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—IGF1—urinary bladder cancer	0.000525	0.00179	CbGpPWpGaD
Tranexamic Acid—Convulsion—Doxorubicin—urinary bladder cancer	0.000523	0.00101	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000522	0.00101	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000518	0.000998	CcSEcCtD
Tranexamic Acid—Arthralgia—Doxorubicin—urinary bladder cancer	0.000513	0.00099	CcSEcCtD
Tranexamic Acid—Chest pain—Doxorubicin—urinary bladder cancer	0.000513	0.00099	CcSEcCtD
Tranexamic Acid—Myalgia—Doxorubicin—urinary bladder cancer	0.000513	0.00099	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—IL2—urinary bladder cancer	0.000513	0.00175	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—RBX1—urinary bladder cancer	0.000511	0.00174	CbGpPWpGaD
Tranexamic Acid—Discomfort—Doxorubicin—urinary bladder cancer	0.000507	0.000978	CcSEcCtD
Tranexamic Acid—Dyspnoea—Methotrexate—urinary bladder cancer	0.000507	0.000977	CcSEcCtD
Tranexamic Acid—Dyspepsia—Methotrexate—urinary bladder cancer	0.0005	0.000965	CcSEcCtD
Tranexamic Acid—Hypotension—Epirubicin—urinary bladder cancer	0.000497	0.000958	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000492	0.000949	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000491	0.000946	CcSEcCtD
Tranexamic Acid—Fatigue—Methotrexate—urinary bladder cancer	0.00049	0.000945	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000485	0.000934	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000483	0.00093	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—TSC1—urinary bladder cancer	0.000481	0.00164	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Epirubicin—urinary bladder cancer	0.000474	0.000914	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000468	0.000903	CcSEcCtD
Tranexamic Acid—Dyspepsia—Epirubicin—urinary bladder cancer	0.000468	0.000903	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000465	0.000896	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—EP300—urinary bladder cancer	0.000461	0.00157	CbGpPWpGaD
Tranexamic Acid—Hypotension—Doxorubicin—urinary bladder cancer	0.00046	0.000887	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000459	0.000885	CcSEcCtD
Tranexamic Acid—Fatigue—Epirubicin—urinary bladder cancer	0.000459	0.000884	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—JAG1—urinary bladder cancer	0.000457	0.00156	CbGpPWpGaD
Tranexamic Acid—Abdominal pain—Methotrexate—urinary bladder cancer	0.000449	0.000866	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000448	0.000864	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—SRC—urinary bladder cancer	0.000448	0.00153	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000439	0.000846	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000438	0.000845	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000435	0.000839	CcSEcCtD
Tranexamic Acid—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000433	0.000835	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000425	0.000819	CcSEcCtD
Tranexamic Acid—Fatigue—Doxorubicin—urinary bladder cancer	0.000424	0.000818	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000423	0.00144	CbGpPWpGaD
Tranexamic Acid—Abdominal pain—Epirubicin—urinary bladder cancer	0.000421	0.000811	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000419	0.000807	CcSEcCtD
Tranexamic Acid—Asthenia—Methotrexate—urinary bladder cancer	0.000408	0.000786	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000406	0.000782	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000402	0.000776	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000392	0.000756	CcSEcCtD
Tranexamic Acid—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000389	0.00075	CcSEcCtD
Tranexamic Acid—Diarrhoea—Methotrexate—urinary bladder cancer	0.000389	0.00075	CcSEcCtD
Tranexamic Acid—Asthenia—Epirubicin—urinary bladder cancer	0.000382	0.000736	CcSEcCtD
Tranexamic Acid—Dizziness—Methotrexate—urinary bladder cancer	0.000376	0.000725	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—KRAS—urinary bladder cancer	0.000371	0.00126	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—S100B—urinary bladder cancer	0.00037	0.00126	CbGpPWpGaD
Tranexamic Acid—Diarrhoea—Epirubicin—urinary bladder cancer	0.000364	0.000702	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000363	0.000699	CcSEcCtD
Tranexamic Acid—Vomiting—Methotrexate—urinary bladder cancer	0.000361	0.000697	CcSEcCtD
Tranexamic Acid—Headache—Methotrexate—urinary bladder cancer	0.000356	0.000686	CcSEcCtD
Tranexamic Acid—Asthenia—Doxorubicin—urinary bladder cancer	0.000353	0.000681	CcSEcCtD
Tranexamic Acid—Dizziness—Epirubicin—urinary bladder cancer	0.000352	0.000678	CcSEcCtD
Tranexamic Acid—Vomiting—Epirubicin—urinary bladder cancer	0.000338	0.000652	CcSEcCtD
Tranexamic Acid—Nausea—Methotrexate—urinary bladder cancer	0.000338	0.000651	CcSEcCtD
Tranexamic Acid—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000337	0.000649	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000334	0.00114	CbGpPWpGaD
Tranexamic Acid—Headache—Epirubicin—urinary bladder cancer	0.000333	0.000642	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—NCOR1—urinary bladder cancer	0.000333	0.00113	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—TP53—urinary bladder cancer	0.00033	0.00112	CbGpPWpGaD
Tranexamic Acid—Dizziness—Doxorubicin—urinary bladder cancer	0.000325	0.000627	CcSEcCtD
Tranexamic Acid—Nausea—Epirubicin—urinary bladder cancer	0.000316	0.000609	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—HRAS—urinary bladder cancer	0.000315	0.00107	CbGpPWpGaD
Tranexamic Acid—Vomiting—Doxorubicin—urinary bladder cancer	0.000313	0.000603	CcSEcCtD
Tranexamic Acid—Headache—Doxorubicin—urinary bladder cancer	0.000308	0.000594	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—TERT—urinary bladder cancer	0.000294	0.001	CbGpPWpGaD
Tranexamic Acid—Nausea—Doxorubicin—urinary bladder cancer	0.000292	0.000564	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—FGFR3—urinary bladder cancer	0.000269	0.000918	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—ESR1—urinary bladder cancer	0.000262	0.000892	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CREBBP—urinary bladder cancer	0.000229	0.000781	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—IGF1—urinary bladder cancer	0.000226	0.000772	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—RHOA—urinary bladder cancer	0.000207	0.000707	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—ERBB2—urinary bladder cancer	0.000192	0.000654	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CXCL8—urinary bladder cancer	0.000182	0.000621	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—IL2—urinary bladder cancer	0.000174	0.000593	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CCND1—urinary bladder cancer	0.00017	0.000578	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MMP9—urinary bladder cancer	0.000165	0.000561	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000164	0.000559	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PTEN—urinary bladder cancer	0.000164	0.000558	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—EP300—urinary bladder cancer	0.000156	0.000532	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—SRC—urinary bladder cancer	0.000152	0.000517	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MYC—urinary bladder cancer	0.000136	0.000464	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—EGFR—urinary bladder cancer	0.000133	0.000454	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—KRAS—urinary bladder cancer	0.000126	0.000428	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TP53—urinary bladder cancer	0.000112	0.000381	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—HRAS—urinary bladder cancer	0.000107	0.000364	CbGpPWpGaD
